Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
35 results
D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369 - Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.371 - Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
- D3.134 - Evaluation of the level of asthma control in the pulmonology-phtisiology department of the Ignace Deen University Hospital
D3.133 - Association between Asthma and Risk of Respiratory Syncytial Virus-Acute Respiratory Infection in Adults 50 Years or Older Before and After the Covid 19-Pandemic in a Midwest Region of the U.S
D3.135 - Nasal and respiratory symptoms, functional features, and sensitization to platinum salts in platinum catalysts manufacturing workers
D3.136 - Worse asthma control in patients with asthma and respiratory allergies in the CAPTURE study: Rationale for developing the RespiratoryAllergyOptimiser
D3.137 - Effectiveness of Dupilumab in improving Quality of Life in patients with "steroid-resistant" asthma and severe atopic dermatitis
D3.138 - Asthma remission in EGPA patients: applicability and concordance of the main international guidelines
D3.139 - Asthma Comorbidities - do they add more cost, A 3-year follow-up study in Réunion Island
D3.140 - Xiaoqinglong Decoction Combined with Yupingfeng Powder Alleviates Allergic Rhinitis Complicated with Asthma by Inhibiting B Lymphocyte Activation via JAK2/STAT1/MHC-II signaling pathway
D3.142 - Differential Impact of Heat-not-Burn Tobacco Products and Conventional Cigarettes on Pulmonary Cells and Immune Response
D3.143 - Seasonal Patterns of Airborne Pollen in Ecuador: Influence of Wet and Dry Seasons on Allergenic Taxa Concentrations
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download